Mach7 Technologies pivots toward recurring H1 revenue
Mach7 Technologies (ASX:M7T) reported total revenue of $13.7 million for H1 FY26, representing a 23% decline a year earlier.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Mach7 Technologies (ASX:M7T) reported total revenue of $13.7 million for H1 FY26, representing a 23% decline a year earlier.
Mesoblast (ASX:MSB) logged total revenue surged to US$51.3 million in H1 FY26, an increase from the US$3.2 million recorded in the prior year period.
Neurizon Therapeutics (ASX:NUZ) commenced dosing for NUZ-001 within the HEALEY ALS platform trial.
Bioxyne (ASX:BXN) announced an upgrade to its FY26 EBITDA guidance, now projected at $16.5–$19 million.
Monash IVF Group (ASX:MVF) has announced its results for the first half of the 2026 financial year, headlined by an underlying net profit after tax of $10.4 million.
Neuren Pharmaceuticals (ASX:NEU) announced strong financial results for the full year 2025, driven by the continued commercial success of DAYBUE.
Ramsay Health Care (ASX:RHC) returns to profit with a $160.7M H1 FY26 result, driven by a surge in Australian hospital performance and a 6.3% dividend increase.
Sigma Healthcare (ASX:SIG) reported a rise in financial performance for the half-year ended Dec. 31, 2025, driven by the integration of Chemist Warehouse and robust retail sales.
The Melbourne-based digital health firm Vitura Health (ASX:VIT) reported total revenue of $67.9 million for the half year to Dec. 31, 2025.
Imricor Medical Systems (ASX:IMR) announced its financial and operational results for the full year 2025.
EBOS Group (ASX:EBO) reported that underlying EBITDA rose by 3.2% to $300 million in the first half of fiscal 2026.
Radiopharm Theranostics (ASX:RAD) has commenced the first-in-human Phase 1/2a clinical trial of its novel radiopharmaceutical, 177Lu-Betabart (RV-01).
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade